Yes, PALEM trial is a confirmatory trial, a confirmatory, a multicenter single-arm confirmatory trial for painful bone metastasis using arterial embolization. This trial has two co-primary endpoints, safety and immediate efficacy. And immediate efficacy is defined as pain relief response at 72 hours. And the second was safety, and the safety was an embolization-related protocol to find severe adverse events...
Yes, PALEM trial is a confirmatory trial, a confirmatory, a multicenter single-arm confirmatory trial for painful bone metastasis using arterial embolization. This trial has two co-primary endpoints, safety and immediate efficacy. And immediate efficacy is defined as pain relief response at 72 hours. And the second was safety, and the safety was an embolization-related protocol to find severe adverse events. And the result, pain relief response at 72 hours was 50.5%. And for the second endpoint, safety, there were no severe adverse events among 190 patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
